News | Patient Monitors | September 09, 2015

Simple Test Predicts Obstructive Sleep Apnea in Hospitalized Heart Failure Patients

Overnight pulse-oximetry correlates with outpatient polysomnography

sleep apnea, pulse oximetery, congestive heart failure, CHF, pulse-oximetry, Thomas Jefferson University

September 9, 2015 — Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF). The results were published in the Journal of American College of Cardiology: Heart Failure.

“Since traditional screenings are not always effective in patients with congestive heart failure, additional tools are needed,” said lead author Sunil Sharma, M.D., FAASM, associate professor of pulmonary medicine in the Sidney Kimmel Medical College at Thomas Jefferson University. “Our team was able to validate a screening strategy that can be instituted during hospitalization and effectively detect sleep disordered breathing among patients with congestive heart failure.”

This study adds to a growing body of research suggesting a connection between sleep disordered breathing and heart failure. “While an estimated 70 percent of patients with congestive heart failure have underlying sleep disordered breathing, only a minority, roughly 2 percent, are diagnosed and treated. Yet early recognition and treatment of this disorder in patients with congestive heart failure has been shown to improve ejection fraction, acute heart failure and may even reduce readmissions and mortality,” Sharma continued.

Consecutive patients admitted for congestive heart failure at Thomas Jefferson University Hospital were screened by respiratory therapists using the STOP-BANG Questionnaire (Snoring, Tiredness during daytime, Observed apnea, high blood Pressure – Body mass index greater than 35, Age greater than 50 years, Neck circumference greater than 40 centimeters and Male gender).

If the patient screened positive, they received a formal sleep consult during their hospital stay and underwent high-resolution pulse-oximetry testing, which assessed the patient’s oxygen desaturation index (ODI). This low-cost device measures how much oxygen is in a patient’s blood. Researchers hypothesized that dips in oxygen levels throughout the night were a sign of obstructive sleep apnea.

Patients with a high ODI were recommended to undergo overnight polysomnography as an outpatient. Of those who followed up with the recommended polysomnography (n=68), 94 percent (n=64) were diagnosed with sleep disordered breathing.

“Patients with congestive heart failure do not always present with traditional symptoms of sleep apnea, like daytime sleepiness and heavy snoring,” said Paul J. Mather, M.D., FACC, FACP, Lubert Family Professor of Cardiology in the Sidney Kimmel Medical College at Thomas Jefferson University and director of the Advanced Heart Failure and Cardiac Transplant Center at the Jefferson Heart Institute. “This study presents cardiologists with a cost-effective clinical pathway to detect sleep disordered breathing while these patients are hospitalized.”

“Our team’s research showed that overnight pulse-oximetry, a simple low cost device used in the hospital setting, correlates well with the gold-standard polysomnography,” said David J. Whellan, M.D., MHS, FACC, FAHA, the James C. Wilson Professor of Medicine in the Sidney Kimmel Medical College at Thomas Jefferson University and senior author on the study. “Future research is need to see if early screening and intervention of sleep disorder breathing, specifically obstructive sleep apnea, can reduce readmissions, morbidity and mortality in patients with congestive heart failure.”

For more information: www.jefferson.edu

Related Content

Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new...
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in...
Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical...
Overlay Init